Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
2.

Aetiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.

Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J.

Am J Respir Crit Care Med. 2019 Dec 16. doi: 10.1164/rccm.201903-0563CI. [Epub ahead of print]

PMID:
31841044
3.

Identifying causation in hypersensitivity pneumonitis: a British perspective.

Barber CM, Burge PS, Feary JR, Parfrey H, Renzoni EA, Spencer LG, Walters GI, Wiggans RE; GB HP Survey Participants.

BMJ Open Respir Res. 2019 Dec 3;6(1):e000469. doi: 10.1136/bmjresp-2019-000469. eCollection 2019.

4.

Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial.

Whitty JA, Rankin J, Visca D, Tsipouri V, Mori L, Spencer L, Adamali H, Maher TM, Hopkinson NS, Birring SS, Farquhar M, Wells AU, Sestini P, Renzoni EA.

Eur Respir J. 2020 Feb 6;55(2). pii: 1901157. doi: 10.1183/13993003.01157-2019. Print 2020 Feb. No abstract available.

PMID:
31699838
5.

Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA.

Eur Respir J. 2020 Feb 20;55(2). pii: 1901681. doi: 10.1183/13993003.01681-2019. Print 2020 Feb. No abstract available.

PMID:
31699833
6.

Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes.

Kampstra NA, van der Nat PB, Dijksman LM, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Zanen P, Wijsenbeek MS, Eijkemans MJC, Biesma DH, van der Wees PJ, Grutters JC.

ERJ Open Res. 2019 Oct 30;5(4). pii: 00094-2019. doi: 10.1183/23120541.00094-2019. eCollection 2019 Oct.

7.

Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults.

Stainer A, Rice A, Devaraj A, Barnett JL, Donovan J, Kokosi M, Nicholson AG, Cairns T, Wells AU, Renzoni EA.

BMC Pulm Med. 2019 Oct 24;19(1):185. doi: 10.1186/s12890-019-0947-y.

8.

Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns.

Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL.

ERJ Open Res. 2019 Sep 16;5(3). pii: 00118-2019. doi: 10.1183/23120541.00118-2019. eCollection 2019 Jul. Review.

9.

Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.

Mackintosh JA, Stainer A, Barnett JL, Renzoni EA.

Semin Respir Crit Care Med. 2019 Apr;40(2):208-226. doi: 10.1055/s-0039-1683431. Epub 2019 May 28.

PMID:
31137061
10.

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease.

Wells A, Devaraj A, Renzoni EA, Denton CP.

Semin Respir Crit Care Med. 2019 Apr;40(2):184-193. doi: 10.1055/s-0039-1684020. Epub 2019 May 28.

PMID:
31137059
11.

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation.

Stock CJW, Michaeloudes C, Leoni P, Durham AL, Mumby S, Wells AU, Chung KF, Adcock IM, Renzoni EA, Lindahl GE.

Biomed Res Int. 2019 Apr 18;2019:1484736. doi: 10.1155/2019/1484736. eCollection 2019.

12.

Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny path.

Renzoni EA, Wells AU.

Respirology. 2019 Jul;24(7):620-621. doi: 10.1111/resp.13584. Epub 2019 May 15. No abstract available.

13.

Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease.

Wijsenbeek MS, Holland AE, Swigris JJ, Renzoni EA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):152-159. doi: 10.1164/rccm.201903-0614PP. Review. No abstract available.

PMID:
31051080
14.

First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative.

Kampstra NA, Grutters JC, van Beek FT, Culver DA, Baughman RP, Renzoni EA, Wuyts W, Kouranos V, Wijsenbeek MS, Biesma DH, van der Wees PJ, van der Nat PB.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000394. doi: 10.1136/bmjresp-2018-000394. eCollection 2019.

15.

The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.

Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.

16.

In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality.

Mackintosh JA, Desai SR, Adamali H, Patel K, Chua F, Devaraj A, Kouranos V, Kokosi M, Margaritopoulos G, Renzoni EA, Wells AU, Molyneaux PL, Kumar S, Maher TM, George PM.

Eur Respir J. 2019 May 23;53(5). pii: 1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May. No abstract available.

PMID:
30923184
17.

Research highlights from the 2018 ERS International Congress: interstitial lung diseases.

Alfaro TM, Moor CC, Alfieri V, Jeny F, Kreuter M, Wijsenbeek MS, Renzoni EA, Bargagli E, Nunes H, Spagnolo P, Bonella F, Molina-Molina M, Antoniou K, Poletti V.

ERJ Open Res. 2019 Feb 18;5(1). pii: 00215-2018. doi: 10.1183/23120541.00215-2018. eCollection 2019 Feb. Review.

18.

Pulmonary fibrosis: Genetic analysis of telomere-related genes, telomere length measurement-or both?

Kannengiesser C, Borie R, Renzoni EA.

Respirology. 2019 Feb;24(2):97-98. doi: 10.1111/resp.13456. Epub 2018 Dec 17. No abstract available.

19.

The potential impact of azithromycin in idiopathic pulmonary fibrosis.

Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, Maher TM, George PM, Renzoni EA, Molyneaux PL.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb. No abstract available.

PMID:
30442715
20.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

21.

Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.

Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, Pavitt MJ, Alfieri V, Canu S, Bonifazi M, Boccabella C, De Lauretis A, Stock CJW, Saunders P, Montgomery A, Hogben C, Stockford A, Pittet M, Brown J, Chua F, George PM, Molyneaux PL, Margaritopoulos GA, Kokosi M, Kouranos V, Russell AM, Birring SS, Chetta A, Maher TM, Cullinan P, Hopkinson NS, Banya W, Whitty JA, Adamali H, Spencer LG, Farquhar M, Sestini P, Wells AU, Renzoni EA.

Lancet Respir Med. 2018 Oct;6(10):759-770. doi: 10.1016/S2213-2600(18)30289-3. Epub 2018 Aug 28.

22.

New treatment paradigms for connective tissue disease-associated interstitial lung disease.

Kouranos V, Miranda G, Corte TJ, Renzoni EA.

Curr Opin Pulm Med. 2018 Sep;24(5):453-460. doi: 10.1097/MCP.0000000000000508. Review.

PMID:
30020142
23.

Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature.

Stock CJW, Renzoni EA.

Eur J Hum Genet. 2018 Jun;26(6):765-777. doi: 10.1038/s41431-018-0104-8. Epub 2018 Feb 23. Review.

24.

Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep.

Piper AJ, Wort SJ, Renzoni EA, Kouranos V.

Respirology. 2018 Apr;23(4):421-433. doi: 10.1111/resp.13273. Epub 2018 Feb 22. Review. No abstract available.

25.

Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization.

Keir GJ, Wort SJ, Kokosi M, George PM, Walsh SLF, Jacob J, Price L, Bax S, Renzoni EA, Maher TM, MacDonald P, Hansell DM, Wells AU.

Respirology. 2018 Jul;23(7):687-694. doi: 10.1111/resp.13250. Epub 2018 Jan 12.

26.

An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.

Maher TM, Oballa E, Simpson JK, Porte J, Habgood A, Fahy WA, Flynn A, Molyneaux PL, Braybrooke R, Divyateja H, Parfrey H, Rassl D, Russell AM, Saini G, Renzoni EA, Duggan AM, Hubbard R, Wells AU, Lukey PT, Marshall RP, Jenkins RG.

Lancet Respir Med. 2017 Dec;5(12):946-955. doi: 10.1016/S2213-2600(17)30430-7. Epub 2017 Nov 14.

27.

Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival.

Khiroya R, Macaluso C, Montero MA, Wells AU, Chua F, Kokosi M, Maher TM, Devaraj A, Rice A, Renzoni EA, Nicholson AG.

Am J Surg Pathol. 2017 Dec;41(12):1683-1689. doi: 10.1097/PAS.0000000000000928.

28.

Pulmonary Sarcoidosis.

Bonifazi M, Gasparini S, Alfieri V, Renzoni EA.

Semin Respir Crit Care Med. 2017 Aug;38(4):437-449. doi: 10.1055/s-0037-1603766. Epub 2017 Jul 27. Review. No abstract available.

PMID:
28750459
29.

Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM.

Trials. 2017 Jun 15;18(1):275. doi: 10.1186/s13063-017-2016-2.

30.

Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial.

Visca D, Tsipouri V, Mori L, Firouzi A, Fleming S, Farquhar M, Leung E, Maher TM, Cullinan P, Hopkinson N, Wells AU, Banya W, Whitty JA, Adamali H, Spencer LG, Sestini P, Renzoni EA.

Trials. 2017 Apr 28;18(1):201. doi: 10.1186/s13063-017-1912-9.

31.

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.

Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, Nicholson AG, Wells AU.

Arthritis Rheumatol. 2017 Aug;69(8):1670-1678. doi: 10.1002/art.40130. Epub 2017 Jul 18.

32.

British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders.

Hurst JR, Verma N, Lowe D, Baxendale HE, Jolles S, Kelleher P, Longhurst HJ, Patel SY, Renzoni EA, Sander CR, Avery GR, Babar JL, Buckland MS, Burns S, Egner W, Gompels MM, Gordins P, Haddock JA, Hart SP, Hayman GR, Herriot R, Hoyles RK, Huissoon AP, Jacob J, Nicholson AG, Rassl DM, Sargur RB, Savic S, Seneviratne SL, Sheaff M, Vaitla PM, Walters GI, Whitehouse JL, Wright PA, Condliffe AM.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):938-945. doi: 10.1016/j.jaip.2017.01.021. Epub 2017 Mar 25. Review.

33.

Idiopathic Pleuroparenchymal Fibroelastosis.

Bonifazi M, Montero MA, Renzoni EA.

Curr Pulmonol Rep. 2017;6(1):9-15. doi: 10.1007/s13665-017-0160-5. Epub 2017 Jan 27. Review.

34.

Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.

Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, Blanchard A, Edwards LM, Stock C, Daccord C, Renzoni EA, Wells AU, Moffatt MF, Cookson WOC, Maher TM.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1640-1650. doi: 10.1164/rccm.201607-1408OC.

35.

Cough in idiopathic pulmonary fibrosis.

van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, Wijsenbeek MS.

Eur Respir Rev. 2016 Sep;25(141):278-86. doi: 10.1183/16000617.0090-2015. Review.

36.

Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis.

Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, Wells AU, Maher TM.

Am J Respir Crit Care Med. 2016 Oct 15;194(8):989-997.

37.

Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4 in pulmonary fibrosis.

Evans IC, Barnes JL, Garner IM, Pearce DR, Maher TM, Shiwen X, Renzoni EA, Wells AU, Denton CP, Laurent GJ, Abraham DJ, McAnulty RJ.

Clin Sci (Lond). 2016 Apr;130(8):575-86. doi: 10.1042/CS20150697. Epub 2016 Jan 7.

38.

Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night.

Schiza S, Mermigkis C, Margaritopoulos GA, Daniil Z, Harari S, Poletti V, Renzoni EA, Torre O, Visca D, Bouloukaki I, Sourvinos G, Antoniou KM.

Eur Respir Rev. 2015 Jun;24(136):327-39. doi: 10.1183/16000617.00009114. Review.

39.

Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease.

Patel AS, Siegert RJ, Bajwah S, Brignall K, Gosker HR, Moxham J, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

J Clin Epidemiol. 2015 Sep;68(9):1019-27. doi: 10.1016/j.jclinepi.2015.03.021. Epub 2015 Apr 10.

PMID:
26004514
40.

Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future.

Staitieh BS, Renzoni EA, Veeraraghavan S.

Ann Med. 2015 Mar;47(2):100-5. doi: 10.3109/07853890.2014.991751. Epub 2015 Jan 22. Review.

41.

Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies.

Bonifazi M, Bravi F, Gasparini S, La Vecchia C, Gabrielli A, Wells AU, Renzoni EA.

Chest. 2015 Mar;147(3):778-791. doi: 10.1378/chest.14-1475. Review.

PMID:
25340385
42.

Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.

Keir GJ, Walsh SL, Gatzoulis MA, Marino PS, Dimopoulos K, Alonso R, Raposeiras-Roubin S, Renzoni EA, Maher TM, Wells AU, Wort SJ.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Jul 8;31(2):82-90.

PMID:
25078636
43.

Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.

Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, Foley C, Yanez-Lopez M, Babalis D, Marino P, Maher TM, Renzoni EA, Spencer L, Elliot CA, Birring SS, O'Reilly K, Gatzoulis MA, Wells AU, Wort SJ; BPHIT Study Group.

Am J Respir Crit Care Med. 2014 Jul 15;190(2):208-17. doi: 10.1164/rccm.201403-0446OC.

44.

Molecular biomarkers in interstitial lung diseases.

De Lauretis A, Renzoni EA.

Mol Diagn Ther. 2014 Oct;18(5):505-22. doi: 10.1007/s40291-014-0109-0. Review.

PMID:
24935523
45.

Rituximab in severe, treatment-refractory interstitial lung disease.

Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA.

Respirology. 2014 Apr;19(3):353-9. doi: 10.1111/resp.12214. Epub 2013 Nov 29.

46.

Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis.

Keir GJ, Garfield B, Hansell DM, Loebinger MR, Wilson R, Renzoni EA, Wells AU, Maher TM.

Thorax. 2014 Mar;69(3):287-8. doi: 10.1136/thoraxjnl-2013-203988. Epub 2013 Sep 12.

PMID:
24029745
47.

Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease.

Lindahl GE, Stock CJ, Shi-Wen X, Leoni P, Sestini P, Howat SL, Bou-Gharios G, Nicholson AG, Denton CP, Grutters JC, Maher TM, Wells AU, Abraham DJ, Renzoni EA.

Respir Res. 2013 Aug 2;14:80. doi: 10.1186/1465-9921-14-80.

48.

The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease.

Patel AS, Siegert RJ, Keir GJ, Bajwah S, Barker RD, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

Respir Med. 2013 Sep;107(9):1438-43. doi: 10.1016/j.rmed.2013.06.009. Epub 2013 Jul 16.

49.

Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment.

Lota HK, Keir GJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Renzoni EA.

Thorax. 2013 Aug;68(8):780-1. doi: 10.1136/thoraxjnl-2013-203265. Epub 2013 Mar 20. No abstract available.

PMID:
23515438
50.

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA.

J Rheumatol. 2013 Apr;40(4):435-46. doi: 10.3899/jrheum.120725. Epub 2013 Feb 1.

PMID:
23378460

Supplemental Content

Loading ...
Support Center